Agoracom Blog Home

Author Archive

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, October 9th, 2021

A weekly summary of Novamind news and media, including the launch of our new Psychedelic Palliative Care program.

October 5, 2021

Self Compassion, Forgiveness, and Judgment Detox

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

October 6, 2021

Novamind Today and Into the Future

CEO Yaron Conforti at the Benzinga Healthcare Small Cap Conference on the progress we’ve been making to increase access to psychedelic medicine.

October 6, 2021

Addressing Mental Health through Emerging Therapies Panel

CEO Yaron Conforti joins a panel of industry leaders at the Benzinga Healthcare Small Cap Conference for this informative discussion.

October 7, 2021

Dr. Reid Robison Keynote at PSYCH Investor Summit

Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.

In addition, we are pleased to be featured in the third edition of PSYCH’s “The Psychedelics as Medicine Report”.

View all media

Novamind Launches New Psychedelic Palliative Care Program

We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.

Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.

“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”

Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.

Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.

“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”

To learn more about the Palliative Program, visit www.novamind.ca/psychedelic-palliative-care

October 7, 2021

Novamind to Present at LD Micro and KCSA Conferences

We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

October 8, 2021

View all press releases

The Psychedelics Industry Could Offer a Whole New Approach to Work

In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”

Psychedelics: Psychiatry of the Future

Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.

How Psychedelics are Returning to the World of Medicine

“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – Fobi AI To Acquire PassWallet, A Leading Android Wallet Pass Issuer With 6M+ Downloads

Posted by AGORACOM-JC at 4:32 PM on Thursday, October 7th, 2021
Fobi AI Inc.

FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space.  From that core technology they have built a technology stack on top of it that is second to none.

They have created multiple successful applications that, for the purposes of this interview, includes their venue management platform that has been deployed at multiple NCAA tournaments, a recent MGM Resorts Championship PGA Event in Las Vega and most recently signed a deal to bring their venue management solutions to the Canadian Hockey League, the world’s largest development hockey league with 9 Million Fan Visits in 2019.  

In this interview we discuss today’s news: Fobi Announces Acquisition of PassWallet, A Leading Android Wallet Pass Issuer With 6,000,000+ Downloads. Deal To Provide Near-Term and Long-Term Revenue Growth

How important is this acquisition? CEO Rob Anson says it best: 

“This represents a key achievement for Fobi and its shareholders. This acquisition of PassWallet positions Fobi as an up and coming leader in the digital wallet space. The company has made great strides this year and this key strategic development positions us extremely well, enabling us to leverage and monetize on a standard ARPU model (average revenue per user). With over 6 million downloads currently, management believes that by leveraging our artificial intelligence and data solutions as well as the integration of Fobi’s marketing power together with the global wallet pass growth rates, that this number will grow significantly in 2022. Coupled with further untapped opportunity and an addressable market of over 150 countries that are currently not serviced by Google Pay, management anticipates that with this acquisition Fobi is now well positioned to expand into the FinTech space.” 

Sit back and watch this powerful interview with CEO Rob Anson AND… Fobi SVP of Corporate Strategy & Corporate Development Richard Lee.

VIDEO – Liquid Avatar $LQID Digital Identity Platform Goes Commercial With Age Verification Products For 8,000 Convenience Stores In Ontario

Posted by AGORACOM-JC at 10:01 AM on Wednesday, October 6th, 2021

12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.

Moreover, the platform also provides both businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).

It sounded great … and definitely sounded like something you could see starting to happen 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.

1.  In March of this year, Google validated the $LQID business model with this stunning announcement:

 Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

With this news, the data privacy and monetization game is underway and LQID sitting in a great position within the industry and the dominant position within the small cap world.  

BUT THAT’S NOT ALL


2.  In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.

Then came the news all Liquid Avatar investors were waiting for: 

Ontario Releases Technology and Standards for Digital Identity which includes: 

  • the creation of a new data authority; 
  • the introduction of a new government-issued digital ID that lets people prove who they are both online and in person.

These 2 announcements out of Google and the Ontario Government officially put both business and government in the digital identity and credentials game.  There is no looking back.

ENTER LIQUID AVATAR – WORKING WITH ONTARIO GOVERNMENT

Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies .  More than just a good idea, $LQID issued a press release announcing the following:

“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”

AND

“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”

ENTER LIQUID AVATAR – OUT OF DEVELOPMENT AND INTO COMMERCIALIZATION WITH 8,000 CONVENIENCE STORES

This morning $LQID released major news on the commercialization side whose title speaks for itself:

Liquid Avatar Partners With Ontario Convenience Stores Association To Provide Digital Age Verification To 8,000 Stores

According to CEO Lucatch, this announcement represents a major inflection point as it signals a shift from development to commercialization, with many more potential deals in discussion.

LQID IS THE LEADING SMALL CAP COMPANY IN MASSIVE PARADIGM SHIFT TOWARD DIGITAL IDENTITY, PRIVACY AND MONETIZATION

Make no mistake about it.  This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own.  The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.

Suddenly it is getting easy to see the genius of Liquid Avatar.

Watch this great interview with CEO David Lucatch.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:29 AM on Saturday, October 2nd, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our 6ᵗʰ clinic in Murray, Utah.

September 28, 2021

Fear, Suffering, and the Value of Struggle

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

September 28, 2021

Dr. Reid Robison presents at the Life Sciences Investor Forum

In case you missed the presentation from our Chief Medical Officer, a recording of the presentation is now available for viewing here.

October 1, 2021

The Rapid Expansion Continues

Novamind CEO, Yaron Conforti, sits down with Agoracom to discuss opening our 6ᵗʰ clinic in Murray, UT and the broader vision for the company.

View all media

Novamind Opens 6ᵗʰ Integrative Psychiatry Clinic, Adds 3ʳᵈ Clinical Research Site

We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).

The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.

“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”

The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.

Learn more about Novamind’s clinical research division here.

September 30, 2021

View all press releases

How Psychedelics Changed my Life

The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”

The Science of Psychedelic Therapy Breaks on Through

Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – HPQ Breakthrough Green Hydrogen Extraction Is “Scalable With No Limits”, Capable Of Powering Homes Or Entire Cities

Posted by AGORACOM-JC at 12:17 PM on Thursday, September 30th, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:

As such, HPQ firmly believes its silicon products will play an important role in the renewable energy revolution.

ENTER HYDROGEN – “SCALABLE WITH NO LIMITS”

To this end, the Company has also set its sights on Hydrogen with the following 2 press releases:

AUGUST HPQ Launches Revolutionary and Breakthrough Green Hydrogen Extraction Technology Venture

SEPTEMBER HPQ Receives TSX Venture Approval to Proceed With EBH2 Green Hydrogen Extraction Technology Venture

How powerful is this Revolutionary & Breakthrough Green Hydrogen? Try “SCALABLE WITH NO LIMITS”

“EBH2 is scalable with no limits.  It can power a small domestic generator up to ships, factories, buildings, cryptocurrency mines with high energy consumption and even cities.”

Independent validation of the technology is expected to be complete over the next 60 days. If successful, HPQ proposes to bundle the energy production capability of EBH2 systems with its silicon production to further reduce the environmental footprint of its developing high purity silicon, nano powders, and other Renewable Energy products.  Moreover, if successful, EBH2 would provide HPQ with “power plant” capabilities that would allow it to produce its products anywhere on the planet.

If that wasn’t enough HPQ added the following:

“all the while opening up new, and massive addressable markets for a system that can produce cheaply green hydrogen, on demand …. The Agreement establishes the terms of the creation of a new Joint venture Company (“NEWCO”) owned by HPQ and EBH2 that will market, sell and service EBH2 systems and products in North America (Canada, Mexico, and the United States).  …. units could readily replace solar panels or standby generators for homeowners.”

Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!

VIDEO – Novamind (NM : CSE) Opens 6th Integrative Psychiatry Clinic, Anticipates 65,000 Visits to Clinic Network This Year

Posted by AGORACOM-JC at 8:53 AM on Thursday, September 30th, 2021

Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.  

The Company anticipates 65,000 visits to its clinics this year. 

Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.” 

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.  

Kiaro, One Of Canada’s Largest Cannabis Retailers, To Leverage The Power Of Fobi Real-time Artificial Intelligence To Transform Their Approach To Cannabis Retail

Posted by AGORACOM-JC at 5:46 PM on Wednesday, September 29th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

“I was blown away by FOBI “  ($KO CEO Daniel Petrov)

“Kiaro has built an amazing tech driven cannabis retail business”  ($FOBI CEO Rob Anson)

If you’re a shareholder of one of these companies, here is what you need to know about each that makes this technology partnership so powerful:

KIARO is one of Canada’s largest retailers of cannabis, with 16 locations and forecasted annual revenue of $42.7 million from these locations, at a gross profit of $13.7M with further growth anticipated.

FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space.  From that core technology they have built a technology stack on top of it that is second to none.

More than just talk, FOBI has completes Integrations with Lightspeed and Shopify to provide real-time Point of Sale data analytics.  Moreover, they recently announced another $250.000 Data Consulting Agreement with Azincourt Energy

TOGETHER they combined forces in this press release “Fobi Signs $240,000 Data Consulting Agreement With Kiaro Holdings, A National Cannabis Retailer With 16 Locations And Forecasted Annual Revenue Of $42.7 Million, To Assist With Development Of Data Warehouse”

How important is this agreement to each other’s success? 

Very. 

Watch this powerful interview with FOBI CEO, Rob Anson and Kiaro CEO Daniel Petrov to find out exactly.

VIDEO – CurrencyWorks Feature Film NFTs Fetch Over $90,000 Creating New Revenue Stream For Film Industry

Posted by AGORACOM-JC at 4:03 PM on Wednesday, September 29th, 2021

CurrencyWorks (CWRK: CSE) (CWRK: OTCQB) builds digital currencies for brands, companies, and communities to empower the free exchange of value between customers and users.  

More than just lip service clients include:  

·  BitRail (Blockchain Platform)  

·  WAX and Topps (NFT collectables)  

·  Barrett-Jackson Auto Auction (NFTs)  

·  FreedomCoin (digital currency)  

·  CSE/ Odyssey Trust (security token)  

·  VUELE (NFTs)  

·  KodakOne (Digital Currency) 

The company just announced that Feature Film NFTs for ZERO CONTACT, Starring Anthony Hopkins Sell for Over $90,000 Creating New Revenue Stream for Film Industry 

On September 24, 2021, bidding began for the Platinum and Elite NFTs. The one-of-one ZERO CONTACT Platinum Edition NFT sold for $56,860.00 USD and the ZERO CONTACT Elite Edition NFTs sold for a total of $36,575.00 USD. Additionally, CurrencyWorks receives an ongoing royalty every time these NFTs are bought and sold. 

What did Cameron Chell, Chairman of CurrencyWorks have to say? 

“We are extremely proud of the ZERO CONTACT NFTs that CurrencyWorks created on VUELE. This is a significant advancement for film distribution and digital collectibles,” said Cameron Chell, co-head of VUELE and Executive Chairman of CurrencyWorks. 

Sit back and watch this powerful interview with company chairman Cameron Chell.

VIDEO – POET Technologies Launches In China To Critical Acclaim, Including Break Through First Customer Commitment

Posted by AGORACOM-JC at 9:33 AM on Wednesday, September 29th, 2021

When 99.8% of investors read the headline to this press release, you couldn’t blame them for not understanding what it meant or how important it is to the future of POET Technologies 

 POET Technologies Launches Its Products and Optical Interposer Platform in China to Critical Acclaim 

But this is the great thing about AGORACOM Beyond The Press Release, which provides investors with a layman’s understanding  the importance of headlines like this to the business of $PTK …. 

Last week in China was an important one for $PTK.  The Company participated in two leading optoelectronics conferences / exhibitions in China at which they introduced POET to the China market (where most of the customers are), and demonstrated their technology across a range of products.

HOW WELL DID THE PRESENTATIONS GO?

That can easily be summarized by this powerful quote:

“The companies that attended the live demos now know who POET is and the significant value that we can provide to them.  We were already engaged with a few customers, such as Fibertop and their commitment to adopt POET optical engines in their optical modules is a breakthrough for us.  Other companies requested samples of our demonstrated products, and several more want to either engage in development contracts that would incorporate POET Optical Engines in their products or have POET incorporate their components into POET’s Optical Engines. Numerous opportunities for increased customer engagement in China, including with some of the largest players,” 

WHAT KIND OF COMPANIES DID POET MEET AND DEMO THEIR PRODUCTS TO IN CHINA

More than 60 C-level and senior R&D executives representing over 20 companies, including:

  • Major China-based network equipment suppliers
  • Tier 1 transceiver module companies
  • Leading optical module and fiber optic companies (several of which are publicly traded)
  • Data center operators … and 
  • Major multi-billion-dollar public enterprise companies seeking to expand into the optical transceiver business

You don’t have to be a computer scientist to understand the potential of these target markets. But you do have to watch this powerful interview in its entirety to understand the big picture.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, September 25th, 2021

A weekly summary of Novamind news and media, including the announcement of our inclusion in the NYSE Listed AdvisorShares Psychedelics ETF and more.

September 21, 2021

Burnout and the wounded healer​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF​

We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).

PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies. 

“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.” 

Additional information on the ETF can be found here.

September 20, 2021

Novamind to Present at Benzinga Healthcare Conference​

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

September 23, 2021

Novamind Announces DTC Eligibility for its Common Shares​

We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers. 

“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”

September 24, 2021

View all press releases

Mental Health, With a Side of Psychedelics?

A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]